Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844388 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare a New Eye Drop Formulation With Refresh Contacts®
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT01844388: Completed Phase 3 study, sponsored by Allergan.
NCT01844388 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 365 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01844388, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
This study will compare the safety and efficacy of a new carboxymethylcellulose based eye drop formula to Refresh Contacts® for lubricating and rewetting contact lenses.
Primary Outcome
Contact lens distance visual acuity was measured for each eye using the LogMAR visual acuity eye chart. The worse eye at Baseline was used for analysis. A change of 0.1 on the LogMAR scale was equivalent to a 1 line change in visual acuity. The following categories are reported: Better=an increase in 2 or more lines, No Change=a change of +/- 1 line, and Worse=a decrease of 2 lines or more.
Interventions
- DRUG carboxymethylcellulose based eye drop formula
- DRUG carboxymethylcellulose sodium based eye drop solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2013-05-29 |
| Est. Completion | 2013-12-02 |
| Phase | Phase 3 |
What the finished NCT01844388 record still lists
NCT01844388 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which carboxymethylcellulose based eye drop formula is the first listed.
NCT01844388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01844388 about?
NCT01844388 is a clinical study titled "A Study to Compare a New Eye Drop Formulation With Refresh Contacts®". This study will compare the safety and efficacy of a new carboxymethylcellulose based eye drop formula to Refresh Contacts® for lubricating and rewetting contact lenses.
What is the current status of trial NCT01844388?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2013-05-29. Estimated completion is 2013-12-02.
What interventions are being tested in trial NCT01844388?
The interventions under investigation include: carboxymethylcellulose based eye drop formula (DRUG), carboxymethylcellulose sodium based eye drop solution (DRUG).
Who is sponsoring clinical trial NCT01844388?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01844388's enrollment target sits among peer trials
365 1001st of 2000 higher than 998 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI